Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258408 | 0.69 | EGFR (0.31) | EGFR | |
| SCHEMBL23309165 | 0.68 | MEN1 (0.32) | EGFR | |
| SCHEMBL4752915 | 0.67 | MEN1 (0.47) | EGFR | |
| SCHEMBL2338585 | 0.65 | MAPT (0.53) | — | |
| SCHEMBL19152162 | 0.65 | EGFR (0.35) | EGFR | |
| SCHEMBL23309191 | 0.64 | MEN1 (0.32) | EGFR | |
| SCHEMBL2402694 | 0.64 | EPHX1 (0.33) | RET | |
| SCHEMBL24743767 | 0.63 | — | — | |
| SCHEMBL3279399 | 0.63 | EGFR (0.33) | EGFR | |
| SCHEMBL3286005 | 0.63 | EGFR (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670150-B2 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN, INC. (US) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274230-A1 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS | FPR2, FPR3, FPR1 | RET 614/4885EGFR 525/4885CNR1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.